US Bancorp DE Reduces Stock Position in Xencor, Inc. (NASDAQ:XNCR)

US Bancorp DE lessened its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 75.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,532 shares of the biopharmaceutical company’s stock after selling 7,843 shares during the quarter. US Bancorp DE’s holdings in Xencor were worth $58,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in XNCR. KBC Group NV increased its position in Xencor by 63.5% during the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 1,213 shares in the last quarter. Thrivent Financial for Lutherans increased its position in Xencor by 127.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 116,369 shares of the biopharmaceutical company’s stock worth $2,340,000 after purchasing an additional 65,180 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Xencor during the 3rd quarter worth about $362,000. Intech Investment Management LLC purchased a new stake in Xencor in the 3rd quarter valued at about $368,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in Xencor by 7.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 626,988 shares of the biopharmaceutical company’s stock valued at $12,609,000 after buying an additional 40,788 shares during the period.

Xencor Stock Down 2.8 %

Shares of NASDAQ:XNCR opened at $12.62 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor, Inc. has a 1 year low of $12.54 and a 1 year high of $27.24. The stock has a market capitalization of $889.23 million, a P/E ratio of -3.94 and a beta of 0.74. The stock has a 50-day simple moving average of $16.92 and a 200-day simple moving average of $20.40.

Xencor (NASDAQ:XNCR) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $52.79 million during the quarter, compared to analysts’ expectations of $17.14 million. Equities analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current year.

Analysts Set New Price Targets

XNCR has been the subject of several recent analyst reports. Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $20.00 to $30.00 in a report on Monday, December 2nd. Wells Fargo & Company lowered their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Finally, StockNews.com cut Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $34.38.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.